Literature DB >> 26842924

Segmental distribution of some common molecular markers for colorectal cancer (CRC): influencing factors and potential implications.

Petros Christakis Papagiorgis1.   

Abstract

Proximal and distal colorectal cancers (CRCs) are regarded as distinct disease entities, evolving through different genetic pathways and showing multiple clinicopathological and molecular differences. Segmental distribution of some common markers (e.g., KRAS, EGFR, Ki-67, Bcl-2, COX-2) is clinically important, potentially affecting their prognostic or predictive value. However, this distribution is influenced by a variety of factors such as the anatomical overlap of tumorigenic molecular events, associations of some markers with other clinicopathological features (stage and/or grade), and wide methodological variability in markers' assessment. All these factors represent principal influences followed by intratumoral heterogeneity and geographic variation in the frequency of detection of particular markers, whereas the role of other potential influences (e.g., pre-adjuvant treatment, interaction between markers) remains rather unclear. Better understanding and elucidation of the various influences may provide a more accurate picture of the segmental distribution of molecular markers in CRC, potentially allowing the application of a novel patient stratification for treatment, based on particular molecular profiles in combination with tumor location.

Entities:  

Keywords:  Biomarkers; Colorectal cancer; Prediction; Prognosis; Treatment; Tumor location

Mesh:

Substances:

Year:  2016        PMID: 26842924     DOI: 10.1007/s13277-016-4913-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  48 in total

Review 1.  The molecular biology of colorectal carcinoma and its implications: a review.

Authors:  Sanjay Harrison; Harrison Benziger
Journal:  Surgeon       Date:  2011-05-24       Impact factor: 2.392

2.  Molecular subtyping of colorectal cancer: time to explore both intertumoral and intratumoral heterogeneity to evaluate patient outcome.

Authors:  Eric R Fearon; John M Carethers
Journal:  Gastroenterology       Date:  2014-11-22       Impact factor: 22.682

3.  Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

Authors:  H Blons; J F Emile; K Le Malicot; C Julié; A Zaanan; J Tabernero; E Mini; G Folprecht; J L Van Laethem; J Thaler; J Bridgewater; L Nørgård-Petersen; E Van Cutsem; C Lepage; M A Zawadi; R Salazar; P Laurent-Puig; J Taieb
Journal:  Ann Oncol       Date:  2014-10-06       Impact factor: 32.976

4.  Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort.

Authors:  Elizabeth H Ruder; Adeyinka O Laiyemo; Barry I Graubard; Albert R Hollenbeck; Arthur Schatzkin; Amanda J Cross
Journal:  Am J Gastroenterol       Date:  2011-03-15       Impact factor: 10.864

5.  Characterization of rectal, proximal and distal colon cancers based on clinicopathological, molecular and protein profiles.

Authors:  P Minoo; I Zlobec; M Peterson; L Terracciano; A Lugli
Journal:  Int J Oncol       Date:  2010-09       Impact factor: 5.650

6.  Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study.

Authors:  Megan M Garrity; Lawrence J Burgart; Michelle R Mahoney; Harold E Windschitl; Muhammad Salim; Martin Wiesenfeld; James E Krook; John C Michalak; Richard M Goldberg; Michael J O'Connell; Alfred F Furth; Daniel J Sargent; Linda M Murphy; Eunice Hill; Darren L Riehle; Cecelia H Meyers; Thomas E Witzig
Journal:  J Clin Oncol       Date:  2004-05-01       Impact factor: 44.544

7.  Stage III & IV colon and rectal cancers share a similar genetic profile: a review of the Oregon Colorectal Cancer Registry.

Authors:  Ute Gawlick; Kim C Lu; Miriam A Douthit; Brian S Diggs; Kathryn G Schuff; Daniel O Herzig; Vassiliki L Tsikitis
Journal:  Am J Surg       Date:  2013-05       Impact factor: 2.565

8.  Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis.

Authors:  Jens Neumann; Laura Wehweck; Susanne Maatz; Jutta Engel; Thomas Kirchner; Andreas Jung
Journal:  Virchows Arch       Date:  2013-08-10       Impact factor: 4.064

Review 9.  Are there two sides to colorectal cancer?

Authors:  Barry Iacopetta
Journal:  Int J Cancer       Date:  2002-10-10       Impact factor: 7.396

10.  Biomarkers in precision therapy in colorectal cancer.

Authors:  Marlies S Reimers; Eliane C M Zeestraten; Peter J K Kuppen; Gerrit Jan Liefers; Cornelis J H van de Velde
Journal:  Gastroenterol Rep (Oxf)       Date:  2013-08-23
View more
  3 in total

1.  Long-term status of predicted body fat percentage, body mass index and other anthropometric factors with risk of colorectal carcinoma: Two large prospective cohort studies in the US.

Authors:  Akiko Hanyuda; Dong Hoon Lee; Shuji Ogino; Kana Wu; Edward L Giovannucci
Journal:  Int J Cancer       Date:  2019-07-23       Impact factor: 7.396

2.  International scientific communications in the field of colorectal tumour markers.

Authors:  Krasimir Ivanov; Ivan Donev
Journal:  World J Gastrointest Surg       Date:  2017-05-27

Review 3.  Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer.

Authors:  Yuji Miyamoto; Koichi Suyama; Hideo Baba
Journal:  Int J Mol Sci       Date:  2017-04-02       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.